CONTACT
+91 80 2808 2808
ContactUs.BBL@biocon.com

U.S. FDA completes surveillance (routine) cGMP inspection of one of our Biologics Drug Product facilities in Bengaluru

  • Posted by: Biocon Biologics

NOTIFICATION TO STOCK EXCHANGE

Company Statement

Bengaluru, Karnataka, India, Aug 31, 2019

“The U.S. FDA conducted a cGMP inspection at one of our Biologics Drug Product facilities in Bengaluru from Aug 22 to Aug 30, 2019. The inspection concluded with four observations which we believe will not impact supplies from this facility. We are confident of addressing these observations through a Corrective and Preventive Action plan in a timely manner.”

– Company Spokesperson

Author: Biocon Biologics
Share